Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) EBT Margin: 2021-2025

Historic EBT Margin for Kiniksa Pharmaceuticals International (KNSA) over the last 4 years, with Sep 2025 value amounting to 15.02%.

  • Kiniksa Pharmaceuticals International's EBT Margin rose 2143.00% to 15.02% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.13%, marking a year-over-year increase of 3188.00%. This contributed to the annual value of -8.54% for FY2024, which is 2518.00% up from last year.
  • Latest data reveals that Kiniksa Pharmaceuticals International reported EBT Margin of 15.02% as of Q3 2025, which was up 2.92% from 14.59% recorded in Q2 2025.
  • In the past 5 years, Kiniksa Pharmaceuticals International's EBT Margin registered a high of 47.14% during Q3 2022, and its lowest value of -253.51% during Q3 2021.
  • Over the past 3 years, Kiniksa Pharmaceuticals International's median EBT Margin value was -6.42% (recorded in 2024), while the average stood at -10.48%.
  • In the last 5 years, Kiniksa Pharmaceuticals International's EBT Margin spiked by 30,065bps in 2022 and then tumbled by 5,982bps in 2023.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's EBT Margin (Quarterly) stood at -233.66% in 2021, then skyrocketed by 17,236bps to -61.30% in 2022, then slumped by 2,507bps to -86.37% in 2023, then soared by 7,252bps to -13.86% in 2024, then skyrocketed by 2,143bps to 15.02% in 2025.
  • Its last three reported values are 15.02% in Q3 2025, 14.59% for Q2 2025, and 11.30% during Q1 2025.